

Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning

<https://marketpublishers.com/r/N86EB590DC6EN.html>

Date: November 2017

Pages: 127

Price: US\$ 4,000.00 (Single User License)

ID: N86EB590DC6EN

Abstracts

The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing prices and ever decreasing margins. In this era of increased pharmaceutical industry competition, success for generic drug companies is dependent on their ability to manufacture therapeutic-equivalent drug products in an economical and timely manner, while also being cognizant of patent infringement and other legal and regulatory concerns. Diversification of product portfolios, vertical integration across the manufacturing process, and expanding their geographic presence, especially into emerging markets are some of the key strategies which can be implemented by the generic companies to overcome the existing challenges.

One of the most initial and important step for the development of a prospective generic drug product comprises of product (Active Pharmaceutical Ingredient-API) selection and identification. API is the primary constituent of a pharmaceutical drug product that governs the final cost of the drug product as well as the commercial profit earned by the company. Early access to high-quality active pharmaceutical ingredients (API) that are not infringing patents is critical to success in regulated finished-dose markets as a significant part of generics' profits is made during the early days of their availability.

Factors which have to be taken into consideration during the generic product evaluation process include:

The total geographical and target disease market size.

Therapeutic areas of the product-whether the drug in question is approved for a

niche condition or is trying to make a space for itself in the already crowded therapy class.

Competitor intelligence.

Current market sales of the innovator product.

Patent/exclusivity time frame.

Complexity in the development and time frames.

Availability of API, equipment and expertise.

Budget required and return on investment.

Keeping in mind the above mentioned elements we have scrutinized and selected 10 drug molecules. This information in the report can aid a prospective generic developer to review and evaluate products which can be incorporated in the company's developmental pipeline.

The therapy classes covered in this report are:

Oncology

Cardiovascular

Respiratory

Gastroenterology

Psychiatry

Infectious disease

The following points were considered while selecting the products:

Blockbuster drugs with a likelihood of lucrative future sales.

Drugs with novel therapeutic approach for rare disease.

Specialized products in niche therapeutic markets with no existing competitors.

Products with robust ongoing clinical trials which will lead to future label expansions and ultimately act as sales booster.

First in class drug products with novel targeting mechanism.

Contents

EXECUTIVE SUMMARY

FACTORS TO BE CONSIDERED DURING THE PRODUCT EVALUATION PROCESS

STAGES IN THE DEVELOPMENT OF A GENERIC DRUG PRODUCT

POTENTIAL CHALLENGES IN THE VARIOUS DEVELOPMENT STAGES

OPPORTUNITY AREAS FOR GENERIC PRODUCT DEVELOPMENT

JAKAFI

MECHANISM OF ACTION

JAKAFI IN MYELOFIBROSIS (MF)

JAKAFI IN POLYCYTHEMIA VERA (PCV)

JAKAFI IN GRAFT-VERSUS-HOST DISEASE (GVHD)

CLINICAL STUDY DATA

The COMFORT-I and –II study

COMFORT-I

The primary end point

Secondary end points

COMFORT –II

RESPONSE trial

The primary end point

The secondary end points

ONGOING RESEARCH PROGRAM

ORKAMBI

CLINICAL STUDY DATA

TRAFFIC and TRANSPORT

PROGRESS STUDY

LABEL EXPANSION TO TREAT 6- TO 11-YEAR-OLD

MARKET PERFORMANCE AND COMPETITION: IMBRUVICA

AN OVERVIEW OF THE FDA APPROVAL HISTORY OF IMBRUVICA

IMBRUVICA IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

IMBRUVICA IN WALDENSTRÖM'S MACROGLOBULINEMIA(WM)

IMBRUVICA IN MANTLE CELL LYMPHOMA (MCL)

IMBRUVICA IN MARGINAL ZONE LYMPHOMA (MZL)

IMBRUVICA IN CHRONIC GRAFT VERSUS HOST DISEASE (cGVHD)

CLINICAL STUDY DATA

MANTLE-CELL LYMPHOMA

The PCYC-1104

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

RESONATE TRIAL: Ibrutinib versus Ofatumumab in Previously Treated Chronic

Lymphoid Leukemia

Long-term follow-up results from the pivotal Phase 3 RESONATE trial

RESONATE-2: Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Updated results from the pivotal Phase 3 RESONATE-2 trial

Imbruvica in Waldenstrom's macroglobulinemia

Imbruvica for Relapsed/Refractory Marginal Zone Lymphoma (MZL)

Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease

IMBRUVICA- ON THE VERGE OF BECOMING A MEGA-BLOCKBUSTER DRUG

MARKET PERFORMANCE AND COMPETITION: ENTRESTO

CLINICAL STUDY DATA

PARADIGM-HF

MARKET PERFORMANCE AND COMPETITION IBRANCE

CLINICAL STUDY DATA

PALOMA-1

PALOMA-2

PALOMA-3

ONGOING RESEARCH

1. The PATINA trial

2. The PALLAS Trial

3. NCT02499120:

EPCLUSA

CLINICAL STUDY DATA

ASTRAL-1

ASTRAL-2 and ASTRAL-3

ASTRAL-4

ASTRAL-5

MARKET PERFORMANCE AND COMPETITORS

LYNPARZA

HARNESSING THE POTENTIAL OF PARP INHIBITORS IN OVARIAN CANCER

CLINICAL STUDY DATA

SOLO-2

Study 19

MARKET PERFORMANCE AND COMPETITION

ONGOING RESEARCH

Lynparza: Paving its way towards BRCA-Mutated Breast Cancer- the OlympiAD trial

PAOLA trial

POLO trial

PROfound trial

CONCERTO trial
UPTRAVI
CLINICAL STUDY DATA
GRIPHON trial
MARKET PERFORMANCE AND COMPETITORS
ONGOING RESEARCH
TRITON trial
TRANSIT TRIAL
INGREZZA
CLINICAL STUDY DATA
KINECT 3
Extension study of INGREZZA 40 mg and INGREZZA 80 mg (Intent-to-treat-ITT population)
MARKET PERFORMANCE AND COMPETITION
T-Forward Study
T-Force GREEN Study
T-Force GOLD study
OCALIVA
CLINICAL STUDY DATA
The POISE trial
Open-Label Extension
MARKET PERFORMANCE AND COMPETITION
FDA concern regarding incorrect dosing of Ocaliva
ONGOING RESEARCH
COBALT trial
REGENERATE trial- effect of Obeticholic Acid treatment on nonalcoholic steatohepatitis (NASH)
FLINT Trial

List Of Figures

LIST OF FIGURES

FIGURE: 1.THE THERAPY CLASSES COVERED IN THIS REPORT

Figure 2 STAGES IN THE DEVELOPMENT OF A GENERIC DRUG PRODUCT

Figure 3 POTENTIAL CHALLENGES IN THE VARIOUS DEVELOPMENT STAGES

Figure 4 JAKAFI KEY POINTS

Figure 5 COMFORT I PRIMARY END POINT

FIGURE 6 COMFORT I SECONDARY END POINT

Figure 7 COMFORT II PRIMARY END POINT

Figure 8 RESPONSE PRIMARY END POINT

Figure 9 ORKAMBI KEY POINTS

Figure 10 EFFICACY RESULTS FROM TRAFFIC AND TRANSPORT

Figure 11 IMBRUVICA KEY POINTS

Figure 12 AN OVERVIEW OF THE FDA APPROVAL HISTORY OF IMBRUVICA

Figure 13 THE PCYC-1104 RESULTS

Figure 14 RESONATE TRIAL-PROGRESSION-FREE AND OVERALL SURVIVAL

FIGURE 15: PROGRESSION-FREE SURVIVAL WITH IBRUTINIB VERSUS
CHLORAMBUCIL.

Figure 16 OVERALL SURVIVAL AND RESPONSE RATES WITH IBRUTINIB VERSUS
CHLORAMBUCIL.

FIGURE 17 ENTRESTO KEY POINTS

Figure 18 PARADIGM-HF: CLINICAL ENDPOINTS

FIGURE 19 IBRANCE KEY POINTS

Figure 20 EPCLUSA KEY POINTS

Figure 21 LYNPARZA KEY POINTS

Figure 22 SOLO-2 TRIALS RESULTS

Figure 23 STUDY 19 RESULTS

Figure 24 UPTRAVI KEY POINTS

Figure 25 PRIMARY ENDPOINT:TIME TO FIRST DISEASE PROGRESSION EVENT
IN THE GRIPHON TRIAL

Figure 26 GRIPHON TRIAL PRIMARY ENDPOINT EVENTS UP TO THE END OF
TREATMENT

Figure 27 INGREZZA KEY POINTS

FIGURE 28 KINECT-3 RESULTS

Figure 29 Results of extension study of INGREZZA

Figure 30 OCALIVA KEY POINTS

FIGURE 31 PRIMARY COMPOSITE END POINT IN THE DOUBLE-BLIND AND OPEN-

LABEL EXTENSION PHASES

FIGURE 32 ALKALINE PHOSPHATASE AND TOTAL BILIRUBIN LEVELS IN THE DOUBLE-BLIND AND OPEN-LABEL EXTENSION PHASES

List Of Tables

LIST OF TABLES

Table 1 LIST OF SELECTED MOLECULES

TABLE 2 JAKAFI PATENT DETAILS

TABLE 3 ORKAMBI PATENT DETAILS

TABLE 4 IMBRUVICA PATENT DETAILS

TABLE 5 ENTRESTO PATENT DETAILS

Table 6 MAJOR TRIALS IN THE FORTIHFY PROGRAM

TABLE 7 IBRANCE PATENT DETAILS

TABLE 8 RESULTS OF PALOMA-2 TRIAL

Table 9 RESULTS OF PALOMA-3 TRIAL

TABLE 10 EPCLUSA PATENT DETAILS

Table 11 ASTRAL TRIALS- STUDY OUTCOME

TABLE 12 LYNPARZA PATENT DETAILS

TABLE 13 UPTRAVI PATENT DETAILS

TABLE 14 INGREZZA PATENT DETAILS

TABLE 15 OCALIVA PATENT DETAILS

TABLE 16-COMPETITIVE LANDSCAPE FOR THE SELECTED MOLECULES

I would like to order

Product name: Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning

Product link: <https://marketpublishers.com/r/N86EB590DC6EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N86EB590DC6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

